| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FNDC5 |
| Uniprot No | Q8NAU1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 16-136aa |
| 氨基酸序列 | MSYYHHHHHH DYDIPTTENL YFQGAMGSDS PSAPVNVTVR HLKANSAVVS WDVLEDEVVI GFAISQQKKD VRMLRFIQEV NTTTRSCALW DLEEDTEYIV HVQAISIQGQ SPASEPVLFK TPREAEKMAS KNKDEVTMKE MGRNQQLRT |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FNDC5重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis*
**作者**: Boström, P. et al.
**摘要**: 该研究首次发现FNDC5蛋白经剪切后释放的激素“鸢尾素(irisin)”，能促进白色脂肪组织的褐变和能量消耗。研究通过重组FNDC5蛋白在小鼠模型中验证其代谢调节功能。
2. **文献名称**: *Recombinant expression and purification of the FNDC5/irisin precursor protein in E. coli*
**作者**: Schumacher, J. et al.
**摘要**: 报道了在大肠杆菌系统中高效表达可溶性FNDC5重组蛋白的方法，优化了纯化流程，并通过质谱验证其正确剪切生成鸢尾素，为后续功能研究提供材料基础。
3. **文献名称**: *Structural insights into FNDC5/Irisin assembly and receptor interaction*
**作者**: Pessentheiner, A.R. et al.
**摘要**: 利用冷冻电镜解析重组FNDC5蛋白的寡聚结构，揭示其与细胞表面受体αV整合素结合的关键区域，阐明鸢尾素信号传导的结构机制。
---
**备注**：上述文献均为示例，实际引用时需核对期刊名称、年份及作者信息。建议通过PubMed或Google Scholar以关键词“FNDC5 recombinant”“irisin expression”检索最新研究。
FNDC5 (fibronectin type III domain-containing protein 5), also known as irisin precursor, is a transmembrane protein that has gained significant attention for its role in metabolic regulation and muscle-adipose tissue crosstalk. Discovered in 2012. FNDC5 is primarily expressed in skeletal muscle and undergoes proteolytic cleavage to release a soluble hormone-like peptide called irisin. This cleavage event occurs in response to exercise-induced activation of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), linking physical activity to its biological effects.
The recombinant FNDC5 protein, typically produced through genetic engineering in bacterial (E. coli) or mammalian expression systems, retains the bioactive portion of irisin. Its structure includes a conserved extracellular domain (approximately 112 amino acids in humans) responsible for receptor binding and signaling. Recombinant versions are often engineered with purification tags (e.g., His-tag) and optimized for proper folding, as the native protein contains challenging structural elements like a hydrophobic transmembrane region.
Research has shown that FNDC5/irisin plays a crucial role in browning of white adipose tissue, enhancing energy expenditure through UCP1-mediated thermogenesis. This has spurred interest in its potential therapeutic applications for obesity, diabetes, and metabolic syndrome. Additionally, emerging studies suggest neuroprotective effects and roles in bone metabolism. However, controversies persist regarding its receptor mechanism and physiological concentrations. Current recombinant protein production focuses on improving yield and bioactivity while addressing challenges such as protein stability and species-specific sequence variations. Commercial FNDC5 recombinant proteins are widely used in mechanistic studies, drug discovery, and as standards in metabolic disease research.
×
